Equity Profile

CTMX

CytomX Therapeutics, Inc.

Health CareBiotechnology$783.7M

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:15 PM EDT

CytomX Therapeutics Misses on Revenue, Stock Down 3.15%

Metric	Actual	Expected	Surprise
EPS	$-0.10	N/A	+29.58%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

CytomX Therapeutics Misses on Revenue, Stock Down 3.15%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.10	N/A	+29.58%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

CytomX Therapeutics reported a narrower-than-expected loss per share, beating EPS estimates by nearly 30%. However, the stock fell by 3.15% following the earnings report, indicating investor concerns despite the EPS surprise. The lack of revenue figures and management commentary may have contributed to the stock's decline.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

APLEReported

Apple Hospitality REIT, Inc.

RecapView

May4

CRBGReported

CytomX Therapeutics Misses on Revenue, Stock Down 3.15%

Metric	Actual	Expected	Surprise
EPS	$-0.10	N/A	+29.58%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

CytomX Therapeutics Misses on Revenue, Stock Down 3.15%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.10	N/A	+29.58%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime